<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Entecavir in the treatment of chronic hepatitis B virus infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Entecavir in the treatment of chronic hepatitis B virus infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Entecavir in the treatment of chronic hepatitis B virus infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna SF Lok, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rafael Esteban, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> is an orally administered cyclopentyl guanosine analog that is used for treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of active disease (based on elevated serum aminotransferases or histology), or advanced fibrosis or cirrhosis based on histology, noninvasive tests (eg, elastography), or clinical findings (eg, decompensation).</p><p>This topic review will discuss the use of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> for treatment of chronic hepatitis B virus infection. A general approach to the treatment of patients with hepatitis B (including other treatment options) is presented separately. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management"</a>.) </p><p class="headingAnchor" id="H1645593947"><span class="h1">THE EFFICACY OF ENTECAVIR IN DIFFERENT PATIENT POPULATIONS</span></p><p class="headingAnchor" id="H2052877747"><span class="h2">Treatment-naïve patients</span></p><p class="headingAnchor" id="H2"><span class="h3">HBeAg-positive chronic hepatitis</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> achieves hepatitis B e antigen (HBeAg) seroconversion in about 20 percent of patients with HBeAg-positive hepatitis B virus (HBV) who have not previously been treated with nucleoside(tide) analogs [<a href="#rid1">1-6</a>]. In addition, one-year treatment is associated with a 5 to 7 log(10) reduction in mean HBV DNA levels and corresponding improvement in liver histology. The rate of virologic resistance is around 1 percent with up to five years of follow-up. </p><p class="headingAnchor" id="H3"><span class="h4">Versus lamivudine</span><span class="headingEndMark"> — </span>A multinational trial included 715 patients with HBeAg-positive chronic HBV who were randomly assigned to <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> (0.5 mg daily) or <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> (100 mg daily) for 48 weeks [<a href="#rid2">2</a>]. Patients were eligible if they had HBV DNA levels ≥3 mEq/mL (approximately 600,000 international units/mL), a serum alanine transaminase (ALT) ≥1.3 times the upper limit of normal, compensated liver disease, and had no or &lt;12 weeks of nucleoside(t)e therapy for HBV previously.</p><p>At week 48, HBeAg seroconversion was observed in 21 percent of the <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> group and 18 percent of the <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> group  (<a class="graphic graphic_table graphicRef59012" href="/d/graphic/59012.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef70763" href="/d/graphic/70763.html" rel="external">table 2</a>). Serum HBV DNA decreased from baseline by an average of 6.86 log(10) compared with 5.39 log(10) in the lamivudine group. Suppression of HBV DNA to less than 0.7 mEq/mL (approximately 140,000 international units/mL) and normalization of serum ALT were observed significantly more often in the entecavir group (91 versus 65 percent and 78 versus 70 percent, respectively). Serum HBV DNA was undetectable by PCR assay in 67 percent of the entecavir group compared with 36 percent in the lamivudine group.</p><p>Histologic improvement (defined as ≥2 point reduction in the Knodell necroinflammatory score) was observed significantly more often in the <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> group (72 versus 62 percent). Serious adverse events were described in 7 percent of patients in both groups.</p><p>Treatment was extended until HBeAg loss or up to 96 weeks in a subset of patients who remained HBeAg positive but had HBV DNA less than 0.7 mEq/mL (ie, less than approximately 140,000 international units/mL) at week 48 [<a href="#rid3">3</a>]. At week 96 or earlier (for patients who achieved HBeAg loss before week 96), HBV DNA was undetectable in a larger proportion of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> versus <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> treated patients (80 versus 39 percent). Normalization of ALT was observed in 87 versus 79 percent, and HBeAg seroconversion in 31 versus 25 percent. The safety profile was similar to lamivudine throughout the observation period.</p><p>Analysis of cumulative responses up to week 96 of all patients originally enrolled into the study found that the proportion of patients achieving HBeAg seroconversion were similar (31 versus 25 percent). However, this analysis did not take into account HBeAg reversion after treatment was stopped.</p><p>A follow-up report described a subset of 146 patients who received continuous therapy for up to five years [<a href="#rid4">4</a>]. The group was comprised mainly of virologic responders but also included 19 patients who failed to respond during the first year of treatment. All patients received <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> 1 mg daily from year 3 onward. During years 3, 4, and 5, an increasing proportion of patients achieved and maintained HBV DNA levels &lt;300 copies/mL (approximately 60 international units/mL) (94 percent by year 5). In addition, 33 additional patients (23 percent) achieved HBeAg seroconversion, and two patients (1.4 percent) lost hepatitis B surface antigen (HBsAg) during continued treatment. These data confirm that continued treatment can result in late HBeAg seroconversion in some patients. In a separate follow-up report that focused on 40 HBeAg-positive patients, all of whom achieved HBV DNA levels of &lt;300 copies/mL (approximately 60 international units/mL) and most of whom had normal aminotransferase levels, treatment with entecavir for five years was associated with a decrease in inflammation as well as fibrosis scores [<a href="#rid5">5</a>]. However, whether these results can be generalized is uncertain since this report included fewer than 10 percent of the original cohort.</p><p class="headingAnchor" id="H4"><span class="h4">Versus adefovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> is associated with a greater degree of reduction of HBV DNA than <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a>. An open-label, comparative trial included 69 antiviral-naïve patients who were randomly assigned to entecavir (0.5 mg daily) or adefovir (10 mg daily) for a minimum of 52 weeks [<a href="#rid7">7</a>]. The mean HBV DNA change from baseline to week 48 was significantly greater with entecavir (-6.23 versus -4.42 log(10) copies/mL). In addition, significantly more patients receiving entecavir achieved undetectable (&lt;300 copies/mL or approximately 60 international units/mL) HBV DNA levels by PCR between weeks 2 to 48. At 48 weeks, only 3 percent of entecavir treated patients had HBV DNA of 10(5) copies/mL (approximately 20,000 international units/mL) or more compared with 47 percent of adefovir treated patients. These data confirmed that entecavir has more potent antiviral activity than adefovir. Adverse events were similar.</p><p class="headingAnchor" id="H1237253516"><span class="h4">Versus tenofovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> and tenofovir appear to have similar efficacy in treatment-naïve patients during the first year of therapy. Meta-analyses comparing these agents have found no significant differences in HBV DNA suppression, ALT decline, HBeAg seroconversion, and toxicity (eg, nephrotoxicity and hypophosphatemia) [<a href="#rid8">8,9</a>]. However, there are no high-quality data directly comparing the long-term efficacy and safety of these agents.</p><p class="headingAnchor" id="H1780756571"><span class="h4">Role of combination therapy</span><span class="headingEndMark"> — </span>There is no clear benefit of combination therapy with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> plus pegylated interferon among HBeAg-positive patients with chronic HBV infection. </p><p class="bulletIndent1"><span class="glyph">●</span>In one randomized, open-label study of 218 treatment-naïve patients from China, patients received 48 weeks of <a class="drug drug_general" data-topicid="10136" href="/d/drug information/10136.html" rel="external">pegylated interferon alfa-2a</a> alone, or with 24 weeks of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> administered prior to or after peginterferon was initiated [<a href="#rid10">10</a>]. Rates of HBeAg seroconversion 24 weeks post-treatment were similar in all three groups: 33 percent in the monotherapy group, 25 percent in the entecavir add-on group, and 26 percent in the entecavir pretreatment group. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another randomized, open-label study, 175 HBeAg-positive patients received <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> monotherapy or entecavir plus <a class="drug drug_general" data-topicid="10136" href="/d/drug information/10136.html" rel="external">pegylated interferon alfa-2a</a> added on between weeks 24 and 48 [<a href="#rid11">11</a>]. There was a nonsignificant increase in response to therapy (defined as HBeAg loss and HBV DNA &lt;200 IU/mL) at week 48 in the add-on compared with the monotherapy group (19 versus 10 percent, respectively). </p><p></p><p>In addition, the use of tenofovir disoproxil plus <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> does not offer any benefit compared with entecavir monotherapy for most treatment-naïve patients. However, some studies suggest this combination may be effective in treatment-naïve patients with high baseline viremia or in patients who have experienced treatment failure to sequential courses of nucleos(t)ide analogue therapy and/or have multi-drug resistant HBV. The use of entecavir in combination with tenofovir is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/3656.html" rel="external">"Tenofovir and adefovir for the treatment of chronic HBV infection", section on 'In combination with other drugs'</a> and  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'While receiving tenofovir or entecavir'</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">HBeAg-negative chronic hepatitis</span><span class="headingEndMark"> — </span>A multinational trial included 648 patients with HBeAg-negative chronic HBV who were randomly assigned to <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> (0.5 mg daily) or <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> (100 mg daily) for up to 96 weeks [<a href="#rid12">12</a>]. Patients were eligible if they had HBV DNA ≥0.7 mEq/mL (approximately 140,000 international units/mL), and ALT level ≥1.3 times the upper limit of normal, compensated liver disease, and had no or &lt;12 weeks of nucleoside(tide) therapy for HBV previously. </p><p>The primary efficacy endpoint, histologic improvement, defined as a ≥2 point reduction in the Knodell necroinflammatory score at 48 weeks, was observed significantly more often in the <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> group (70 versus 61 percent)  (<a class="graphic graphic_table graphicRef59012" href="/d/graphic/59012.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef70763" href="/d/graphic/70763.html" rel="external">table 2</a>). The mean reduction in HBV DNA was significantly greater in the entecavir group, and undetectable HBV DNA by PCR occurred significantly more often (90 versus 72 percent). Serum HBV DNA decreased by 5.04 log(10) in the entecavir group compared with 4.53 log(10) in the <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> group. The proportion of patients with ALT normalization was significantly higher in the entecavir group (90 versus 72 percent). Serious adverse events were comparable (6 versus 8 percent). Long-term responses are unclear because most patients were taken off treatment at the end of year one. In a follow-up report, most responders who discontinued treatment after 48 weeks had a relapse of HBV DNA within 24 weeks [<a href="#rid13">13</a>]. In a separate follow-up report that included 17 HBeAg-negative patients, all of whom achieved HBV DNA levels of &lt;300 copies/mL (approximately 60 international units/mL) and most of whom had normal aminotransferase levels, treatment with entecavir for five years was associated with a decrease in inflammation as well as fibrosis scores [<a href="#rid5">5</a>]. </p><p>Multiple prospective and retrospective cohort studies assessing the efficacy and safety of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> in nucleos(t)ide-naïve chronic HBV patients that would not have been included in the initial phase III trials have also demonstrated high rates of virologic and serologic responses and a low incidence of resistance [<a href="#rid14">14-16</a>].</p><p class="headingAnchor" id="H967791337"><span class="h2">Treatment-experienced patients</span></p><p class="headingAnchor" id="H6"><span class="h3">Patients previously treated with lamivudine</span><span class="headingEndMark"> — </span>We typically avoid <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> in patients who have been previously treated with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> monotherapy. For such patients, tenofovir is generally preferred. (See  <a class="medical medical_review" href="/d/html/3656.html" rel="external">"Tenofovir and adefovir for the treatment of chronic HBV infection"</a>.) </p><p>This is particularly important for those with confirmed lamivudine-resistant virus (see <a class="local">'Resistance'</a> below), because the efficacy of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> (even when dosed at 1 mg per day) is lower, and the risk of developing entecavir resistance is greater (up to 50 percent after five years), compared with those who are lamivudine-naïve [<a href="#rid17">17-19</a>]. The recommendation to avoid entecavir in patients with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> resistance is supported by both the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) [<a href="#rid20">20,21</a>]. </p><p>A detailed discussion of the management of patients with lamivudine-resistant HBV is found elsewhere. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Persistent viremia/breakthrough infection'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Patients previously treated with adefovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> can be used in patients who have resistance to <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a> but should <strong>not</strong> be used in patients who have prior resistance to <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>. Although this recommendation is supported by both the AASLD and the EASL [<a href="#rid20">20,21</a>], the use of entecavir in this setting is based upon limited data.</p><p class="headingAnchor" id="H3733561508"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H8"><span class="h3">Patients with HIV</span><span class="headingEndMark"> — </span>Experience with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> in patients with HIV and HBV is limited. Although the original package insert for entecavir indicated no anti-HIV activity by in vitro testing at clinically relevant concentrations, a one-log drop in HIV RNA was reported in three separate patients who were taking entecavir monotherapy. In one of these patients, there was selection of a lamivudine-resistant M184V HIV variant [<a href="#rid22">22</a>]. Data from this study and subsequent studies show that entecavir should not be used in patients with HIV and HBV who are not receiving fully suppressive antiretroviral regimens. (See  <a class="medical medical_review" href="/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV"</a>.)</p><p class="headingAnchor" id="H84530367"><span class="h3">Severe exacerbation</span><span class="headingEndMark"> — </span>Antiviral therapy should be initiated as soon as possible in patients with severe exacerbations. Given the need for long-term therapy, we recommend <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> or tenofovir. Several studies have shown that entecavir is safe and effective in the management of severe exacerbations of chronic HBV [<a href="#rid23">23-25</a>]. Interferon should not be used in this setting. More detailed information on patient management is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Choice of initial agent'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Decompensated cirrhosis</span><span class="headingEndMark"> — </span>In patients with decompensated cirrhosis, the virologic and clinical outcomes with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> are comparable to tenofovir and better than <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a> and <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>. These findings are highlighted in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 13 trials that included 873 patients compared <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> for the treatment of HBV-related decompensated cirrhosis [<a href="#rid26">26</a>]. Entecavir produced significantly lower HBV DNA levels and significantly less drug resistance (0.3 versus 14.3 percent) as compared with lamivudine. Entecavir also resulted in nonsignificantly greater HBeAg seroconversion (32 versus 25 percent at 48 weeks) and lower mortality (6.4 versus 7.9 percent). Both drugs significantly improved liver function, and both were safe and well tolerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized, open-label study compared <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> (1 mg daily) with <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a> (10 mg daily) in 191 patients with HBV and decompensated cirrhosis for up to 96 weeks [<a href="#rid27">27</a>]. The entecavir group had a greater decline in HBV DNA levels and was more likely to achieve an HBV DNA level of &lt;300 copies/mL (approximately 60 international units/mL; 57 versus 20 percent at week 48). About two-thirds of patients in both groups showed either improvement or stabilization in Child-Turcotte-Pugh status. Adverse events were similar between the groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A phase II randomized double-blind study evaluated safety in 112 patients with decompensated liver disease who were assigned to treatment with tenofovir, tenofovir plus <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, or <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> [<a href="#rid28">28</a>]. Tenofovir and entecavir were both well tolerated and associated with similar improvements in virological, biochemical, and clinical features.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One study included 70 treatment-naïve patients who received <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> (0.5 mg daily) for one year [<a href="#rid29">29</a>]. During the course of follow-up, 15 patients dropped out (nine because of death or the need for liver transplantation, and six were lost to follow-up). Of the remaining 55 patients, 49 percent had improvement in Child-Turcotte Pugh score of ≥2 points. On intention-to-treat analysis, 92 percent became HBV DNA negative, and 54 percent lost HBeAg. Adverse events were not discussed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study compared clinical outcomes in 482 entecavir-treated and 69 treatment-naïve patients (ie, historical controls who were untreated) with cirrhosis [<a href="#rid30">30</a>]. Entecavir-treated patients who achieved viral suppression had a reduced risk of all clinical outcomes (hazard ratio [HR] 0.51; 95% CI 0.34-0.78), including hepatocellular carcinoma and mortality (liver-related and all-cause mortality).</p><p></p><p>Although <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> is well tolerated in most patients with cirrhosis, entecavir can result in severe lactic acidosis when used in patients with decompensated cirrhosis [<a href="#rid31">31</a>]. Lactic acidosis may be a class effect of nucleosides and/or related to sepsis, which occurs commonly in hospitalized patients with decompensated cirrhosis. (See <a class="local">'Safety'</a> below and  <a class="medical medical_review" href="/d/html/3765.html" rel="external">"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors", section on 'Hyperlactatemia and lactic acidosis'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Patients with minimally elevated ALT levels</span><span class="headingEndMark"> — </span>Guidelines for the management of chronic HBV recognize that the degree of elevation of serum aminotransferases is predictive of the likelihood of response. Patients with low alanine transaminase (ALT) levels who are in the immune tolerant phase of infection tend to respond less well than those with elevated ALT levels. The indications for treatment of chronic HBV are discussed separately. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Indications for antiviral therapy'</a>.) </p><p>The efficacy of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> in patients with a low ALT level has not been extensively studied. However, a subset analysis that included 336 patients who had been treated as part of the phase III trial of entecavir and whose ALT was 1.3 to 2 times the upper limit of normal found that responses among HBeAg-negative patients were similar to those with higher ALT levels, while they were significantly lower in HBeAg-positive patients [<a href="#rid32">32</a>].</p><p>While these data suggest a potential benefit of treatment in patients with minimally elevated ALT, most patients will require many years of treatment to achieve the desired therapeutic endpoint. More studies are needed to determine whether the benefits of initiating treatment in patients with minimally elevated ALT on clinical outcomes are superior to deferring treatment until patients have higher ALT (eg, &gt;2 times upper limit of normal), particularly in HBeAg-positive patients. Until further data are available, the decision to initiate treatment for patients with mildly elevated ALT levels should be individualized and will be influenced by the patient’s age, HBV DNA level, and severity of liver disease [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">RESISTANCE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> monotherapy is associated with a low rate of drug resistance in nucleoside-naïve patients (approximately 1 percent after five years treatment), but a high rate of resistance in lamivudine-refractory patients (approximately 50 percent after five years of treatment). </p><p class="bulletIndent1"><span class="glyph">●</span>No resistance was observed after 48 weeks of treatment in the two large multinational trials of nucleoside-naïve patients described above [<a href="#rid2">2,12</a>]. (See <a class="local">'HBeAg-positive chronic hepatitis'</a> above and <a class="local">'HBeAg-negative chronic hepatitis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A report from the manufacturer updated their resistance analysis in patients who had received up to five years of treatment [<a href="#rid17">17</a>]. In nucleoside-naïve patients, genotypic resistance and genotypic resistance associated with virologic breakthrough were observed in 1.2 and 0.8 percent, respectively. However, these rates may be artificially low because some nonresponders were excluded from the analysis and, in some patients, the <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> dose was higher (ie, 1 mg daily) than commonly used in nucleoside-naïve patients (0.5mg daily). By contrast, genotypic resistance rates were much higher in patients with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> resistance; in such patients, the five-year cumulative probability of genotypic resistance to entecavir and genotypic resistance associated with virologic breakthrough were 51 and 43 percent, respectively. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resistance was observed in only 0.4 percent of patients in a study of 474 nucleoside-naïve patients (47 percent hepatitis B e antigen [HBeAg] positive) followed for four years [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 161 chronic hepatitis B patients receiving <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> monotherapy, 43 had previously been treated with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> [<a href="#rid19">19</a>]. Patients with lamivudine-resistant mutations at the start of entecavir monotherapy had a reduced probability of achieving a virologic response compared with lamivudine-naïve patients (HR 0.14; 95% CI 0.04-0.58). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, 50 patients with compensated chronic hepatitis B virus (HBV; 80 percent HBeAg positive) were switched to <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> after developing adefovir-resistant mutations during <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a> monotherapy for lamivudine-refractory HBV [<a href="#rid34">34</a>]. Only 22 percent of patients achieved a complete virologic response (defined as HBV DNA &lt;60 international units/mL) after 12 months. </p><p></p><p>When resistance to <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> does develop, it appears to occur through a two-hit mechanism. Initially, mutants that are resistant to <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> (rtM204V/I) are selected because they are less sensitive to entecavir. During continued treatment, additional mutations at rtI169, rtT184, rtS202, and/or rtM250 are selected [<a href="#rid35">35-37</a>]. Entecavir resistant strains appear to be sensitive to <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a> and to tenofovir [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H12"><span class="h1">SAFETY</span><span class="headingEndMark"> — </span>Overall, <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> is well tolerated [<a href="#rid38">38-41</a>]. Adverse events were infrequently observed in a study of 1051 patients who were exposed to entecavir for a median of 3.5 years [<a href="#rid38">38</a>]. In this study:</p><p class="bulletIndent1"><span class="glyph">●</span>Four percent of adverse events were considered attributable to <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most adverse events were considered to be mild to moderate and included headache, upper respiratory tract infection, cough, nasopharyngitis, fatigue, and upper abdominal pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On-treatment alanine transaminase (ALT) flares occurred in 3 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One percent of patients discontinued treatment due to an adverse event (compared with 4 percent in lamivudine-treated patients).</p><p></p><p>Severe lactic acidosis has been reported in a case series of patients with advanced cirrhosis (MELD score ≥20) [<a href="#rid31">31</a>]. Lactic acid level was not monitored in several trials of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> in patients with decompensated cirrhosis, but clinical manifestations suggestive of severe lactic acidosis were not observed. Entecavir should be used with caution in patients with decompensated liver disease and always be adjusted for creatinine clearance. (See <a class="local">'Dose'</a> below.)</p><p>Studies in mice found an increased risk of lung adenomas (at exposures 3 to 40 times those in humans). In addition, hepatocellular carcinomas were increased in male mice, while brain gliomas were induced in male and female rats. However, increased risks of cancers have not been observed in studies of patients who have received long-term treatment with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>. In one trial that compared 6216 patients who received entecavir with 6162 patients who received standard of care hepatitis B virus (HBV) nucleos(t)ide analog therapy and followed them for up to 10 years, there were no differences in hepatocellular carcinoma or other malignant neoplasms [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H18334592"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>We do not recommend the use of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> during pregnancy. Teratogenic effects have been observed in animal studies. A detailed discussion on the management of hepatitis B virus in pregnancy is found elsewhere. (See  <a class="medical medical_review" href="/d/html/83476.html" rel="external">"Hepatitis B and pregnancy"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">DOSE</span><span class="headingEndMark"> — </span>The recommended dose of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> is 0.5 mg daily for most nucleoside-naïve patients. A higher dose (1 mg) should be administered to patients with decompensated liver disease. The dose of entecavir should be adjusted in patients with a creatinine clearance &lt;50 mL/min, as well as those on hemodialysis or continuous ambulatory peritoneal dialysis as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>CrCl 30 to 49 mL/minute: Administer 50 percent of usual dose daily or administer the normal dose every 48 hours </p><p class="bulletIndent1"><span class="glyph">●</span>CrCl 10 to 29 mL/minute: Administer 30 percent of usual dose daily or administer the normal dose every 72 hours </p><p class="bulletIndent1"><span class="glyph">●</span>CrCl &lt;10 mL/minute (including hemodialysis and CAPD): Administer 10 percent of usual dose daily or administer the normal dose every 7 days; administer after hemodialysis </p><p></p><p class="headingAnchor" id="H352500225"><span class="h1">VIROLOGIC RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>For patients on <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>, the American Association for the Study of Liver Disease (AASLD) considers an initial virologic response as an undetectable hepatitis B virus (HBV) DNA after 96 weeks of treatment [<a href="#rid20">20</a>]. Although most hepatitis B e antigen (HBeAg)-negative patients have undetectable HBV DNA after 48 weeks of treatment, some HBeAg-positive patients with high baseline HBV DNA may remain viremic at week 96. However, entecavir-resistant virus rarely occurs in treatment-naïve patients (see <a class="local">'Resistance'</a> above). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter cohort study that included 175 nucleoside-naïve patients on <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>, 36 (21 percent) had a detectable viral load at 48 weeks (defined by the investigators as an HBV DNA &gt;80 international units/mL) [<a href="#rid14">14</a>]. Of these 36 patients, 29 (81 percent) achieved an undetectable HBV DNA by approximately three years without modifications in their regimen or the development of resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients from six phase II and III clinical studies that evaluated the safety and efficacy of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> were monitored for resistance through year 5 [<a href="#rid17">17</a>]. In nucleoside-naïve patients, the cumulative probability of genotypic entecavir resistance was approximately 1 percent, even though 10 percent of patients had detectable HBV DNA (ie, ≥300 copies/mL or ≥60 international units/mL) at 48 weeks. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 1254 treatment-naïve individuals on <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>, most had a satisfactory response to therapy. Of the 16 primary nonresponders (using 2009 AASLD-based criteria), all achieved a virologic response (to &lt;15 international units/mL) by 54 months without altering therapy [<a href="#rid43">43</a>].</p><p></p><p>The approach to patient monitoring and the management of patients with persistent viremia are presented separately. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Monitoring on therapy'</a> and  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Persistent viremia/breakthrough infection'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">OPTIMAL DURATION OF THERAPY</span><span class="headingEndMark"> — </span>We determine the optimal duration of therapy for patients with chronic hepatitis B virus (HBV) based upon their hepatitis B e antigen (HBeAg) status as well as the presence or absence of cirrhosis. These issues are discussed elsewhere in detail. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Duration and treatment endpoints'</a>.)</p><p class="headingAnchor" id="H584585262"><span class="h1">RISK OF RELAPSE AFTER DISCONTINUING ENTECAVIR</span><span class="headingEndMark"> — </span>Patients who discontinue treatment with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> must be monitored closely for relapse regardless of their hepatitis B e antigen (HBeAg) status [<a href="#rid44">44-48</a>]. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 169 individuals who were treated with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> for a median 181 weeks, 35 patients with a virologic response discontinued treatment [<a href="#rid45">45</a>]. Nine of the patients who discontinued treatment (26 percent) had virologic relapse. All of those who relapsed were HBeAg positive at baseline and had loss of HBeAg prior to treatment discontinuation. Relapse occurred after a median of 48 weeks off of treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 95 HBeAg-negative individuals who discontinued <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> treatment after a median of 721 days found that a clinical relapse occurred in 45 percent of patients; most relapses occurred more than six months after stopping entecavir [<a href="#rid46">46</a>]. A low baseline hepatitis B virus (HBV) DNA (ie, ≤2x10<sup>5 </sup>international units/mL) was the only independent predictor of a sustained response; however, 29 percent of patients with a lower baseline HBV DNA still experienced relapse. </p><p></p><p>Virological relapses appear to occur later in both HBeAg-positive and HBeAg-negative patients who discontinue therapy with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> compared with tenofovir, though the overall rates of virologic and clinical relapse are similar [<a href="#rid47">47-49</a>]. In a prospective observational study of 100 patients discontinuing tenofovir or entecavir after three years, the risks of virologic and clinical relapse were significantly higher at three months in those receiving tenofovir versus entecavir (53 versus 6 percent and 15 versus 2 percent, respectively); however, relapse rates at 12 and 24 months were comparable [<a href="#rid49">49</a>]. As an example, at 24 months, cumulative rates of virologic and clinical relapse in patients who discontinued tenofovir and entecavir were 72 versus 65 percent and 41 versus 46 percent, respectively. In this study, the total duration of treatment and the duration of consolidation treatment were not predictors of relapse.</p><p>For individuals who experience a virologic relapse, we use the same criteria for reinitiating therapy as we do when initiating therapy for the first time. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Indications for antiviral therapy'</a>.)</p><p class="headingAnchor" id="H1192948044"><span class="h1">EFFECT ON LONG-TERM OUTCOMES</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> is associated with improved long-term outcomes. In a cohort study that included 1951 White European patients with chronic hepatitis B virus (HBV), overall eight-year survival was 94 percent in patients who received at least 12 months of entecavir or tenofovir [<a href="#rid50">50</a>], which is similar to that of the general population. In addition, one study found there was a significant decrease in the risk of developing hepatocellular carcinoma (HCC) in patients with compensated cirrhosis who received at least five years of therapy, with a decrease from 3.2 percent per year during the first five years to 1.6 percent per year between years 5 and 8 [<a href="#rid51">51</a>]. All HCCs occurred in patients older than 50 years of age at the start of entecavir or tenofovir. Factors that were independently associated with a higher risk of HCC after year 5 included older age, lower platelet count at baseline and at year 5, and liver stiffness ≥12 kPa (based on transient elastography) at year 5. In this study, no change in the incidence of HCC after year 5 was observed in patients who did not have cirrhosis pretreatment; however, it is possible that a longer duration of treatment is needed to show a change since the incidence of HCC is lower in these patients. </p><p>Studies evaluating the risk of HCC in patients receiving <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> versus tenofovir have demonstrated conflicting results [<a href="#rid52">52-54</a>]. Some studies have found a lower incidence of HCC in patients receiving tenofovir compared to entecavir, despite propensity score matching [<a href="#rid55">55</a>]; however, these findings are mainly from studies in Asia but not in studies from Europe or North America [<a href="#rid56">56-58</a>]. As an example, in a population-based cohort study in Korea involving approximately 24,000 patients, patients who received tenofovir had improved outcomes compared with those who received entecavir [<a href="#rid55">55</a>]. In this study, tenofovir was associated with a significantly lower risk of HCC (hazard ratio [HR] 0.61; 95% CI 0.54-0.70) and all-cause mortality or transplant (HR 0.77; 95% CI 0.65-0.92). In contrast, a European study involving 772 patients who received entecavir and 1163 who received tenofovir found that cumulative rates of HCC up to 12 years were not different between the two groups, nor were rates of biochemical or virologic remission, hepatitis B surface antigen (HBsAg) loss, liver transplantation, or death [<a href="#rid58">58</a>]. It is likely that the difference observed in Asian studies is an era effect, because tenofovir was approved almost one decade later than entecavir in Asia compared to a delay of three years in Europe and North America. (See  <a class="medical medical_review" href="/d/html/3656.html" rel="external">"Tenofovir and adefovir for the treatment of chronic HBV infection", section on 'Effect on clinical outcomes'</a>.)</p><p class="headingAnchor" id="H986434727"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111626.html" rel="external">"Society guideline links: Management of hepatitis B"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use in treatment naïve patients</strong> – <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> is an orally administered cyclopentyl guanosine analog that is used for the treatment of chronic hepatitis B virus (HBV) infection in adults with evidence of active viral replication and either evidence of active inflammation or advanced fibrosis or cirrhosis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Monotherapy with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> (0.5 mg daily for 52 weeks) in patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic HBV infection was associated with a 5 to 7 log(10) reduction in mean HBV DNA levels. This degree of reduction is greater than what has been observed with <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a> dipivoxil or <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> but appears to be similar to that of <a class="drug drug_general" data-topicid="9488" href="/d/drug information/9488.html" rel="external">telbivudine</a> or tenofovir. (See <a class="local">'HBeAg-positive chronic hepatitis'</a> above and <a class="local">'HBeAg-negative chronic hepatitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for treatment-experienced patients</strong> – <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> should not be used for treatment of patients with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> resistant HBV since entecavir efficacy is lower and the risk of developing entecavir resistance is greater when compared with those who are lamivudine naïve. Tenofovir is preferred in these patients with lamivudine resistance. (See <a class="local">'Patients previously treated with lamivudine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of developing resistance</strong> – Resistance to <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> is rare (approximately 1 percent after five years treatment) in nucleoside-naïve patients but common (approximately 50 percent after five years treatment) in lamivudine-refractory patients. (See <a class="local">'Resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosage</strong> – For most nucleoside-naïve adults and adolescents older than 16 years of age, the dose of <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> is 0.5 mg once daily. A higher dose of entecavir (1 mg) should be used for patients with decompensated liver disease. The dose of entecavir should be adjusted in patients with a creatinine clearance of &lt;50 mL/min as described above. (See <a class="local">'Dose'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration</strong> – We determine the optimal duration of therapy for patients with chronic HBV based upon their HBeAg status as well as the presence or absence of cirrhosis. All patients who discontinue treatment with <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> must be monitored closely for relapse. (See <a class="local">'Optimal duration of therapy'</a> above and <a class="local">'Risk of relapse after discontinuing entecavir'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106:1264.</a></li><li><a class="nounderline abstract_t">Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001.</a></li><li><a class="nounderline abstract_t">Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437.</a></li><li><a class="nounderline abstract_t">Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422.</a></li><li><a class="nounderline abstract_t">Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886.</a></li><li><a class="nounderline abstract_t">Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 2016; 43:134.</a></li><li><a class="nounderline abstract_t">Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49:72.</a></li><li><a class="nounderline abstract_t">Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One 2014; 9:e98865.</a></li><li><a class="nounderline abstract_t">Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 2016; 63:284.</a></li><li><a class="nounderline abstract_t">Xie Q, Zhou H, Bai X, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. Clin Infect Dis 2014; 59:1714.</a></li><li><a class="nounderline abstract_t">Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology 2015; 61:1512.</a></li><li><a class="nounderline abstract_t">Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011.</a></li><li><a class="nounderline abstract_t">Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50:289.</a></li><li><a class="nounderline abstract_t">Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011; 54:443.</a></li><li><a class="nounderline abstract_t">Ridruejo E, Adrover R, Cocozzella D, et al. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract 2011; 65:866.</a></li><li><a class="nounderline abstract_t">Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012; 19:377.</a></li><li><a class="nounderline abstract_t">Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49:1503.</a></li><li><a class="nounderline abstract_t">Lee JH, Cho Y, Lee DH, et al. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother 2014; 58:1730.</a></li><li><a class="nounderline abstract_t">Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52:493.</a></li><li><a class="nounderline abstract_t">Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63:261.</a></li><li><a class="nounderline abstract_t">European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167.</a></li><li><a class="nounderline abstract_t">Jain MK, Zoellner CL. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV. AIDS 2007; 21:2365.</a></li><li><a class="nounderline abstract_t">Chen CH, Lin CL, Hu TH, et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 2014; 60:1127.</a></li><li><a class="nounderline abstract_t">Huang KW, Tam KW, Luo JC, Kuan YC. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2017; 51:539.</a></li><li><a class="nounderline abstract_t">Park JG, Lee YR, Park SY, et al. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. Dig Liver Dis 2018; 50:163.</a></li><li><a class="nounderline abstract_t">Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013; 19:6665.</a></li><li><a class="nounderline abstract_t">Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54:91.</a></li><li><a class="nounderline abstract_t">Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53:62.</a></li><li><a class="nounderline abstract_t">Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52:176.</a></li><li><a class="nounderline abstract_t">Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58:1537.</a></li><li><a class="nounderline abstract_t">Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50:2001.</a></li><li><a class="nounderline abstract_t">Wu IC, Lai CL, Han SH, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51:1185.</a></li><li><a class="nounderline abstract_t">Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 2012; 57:508.</a></li><li><a class="nounderline abstract_t">Heo NY, Lim YS, Lee HC, et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53:449.</a></li><li><a class="nounderline abstract_t">Colonno RJ, Rose RE, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients (abstract). Hepatology 2006; 44 (Suppl 1):229A.</a></li><li><a class="nounderline abstract_t">Warner N, Locarnini SA, Edwards R, et al. Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy (abstract). Hepatology 2004; 40 (Suppl 1):245A.</a></li><li><a class="nounderline abstract_t">Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48:3498.</a></li><li><a class="nounderline abstract_t">Manns MP, Akarca US, Chang TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012; 11:361.</a></li><li><a class="nounderline abstract_t">Kim CW, Kim CS, Kim HY, et al. Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Korean J Intern Med 2018; 33:91.</a></li><li><a class="nounderline abstract_t">Lampertico P, Berg T, Buti M, et al. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Aliment Pharmacol Ther 2020; 52:500.</a></li><li><a class="nounderline abstract_t">Geng J, Bao H, Chen Y, et al. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2020; 18:823.</a></li><li><a class="nounderline abstract_t">Hou JL, Zhao W, Lee C, et al. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol 2020; 18:457.</a></li><li><a class="nounderline abstract_t">Yang YJ, Shim JH, Kim KM, et al. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology 2014; 59:1303.</a></li><li><a class="nounderline abstract_t">Qiu YW, Huang LH, Yang WL, et al. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016; 43:43.</a></li><li><a class="nounderline abstract_t">Ridruejo E, Marciano S, Galdame O, et al. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat 2014; 21:590.</a></li><li><a class="nounderline abstract_t">Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013; 58:1888.</a></li><li><a class="nounderline abstract_t">Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, et al. Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. J Infect Dis 2018; 218:1480.</a></li><li><a class="nounderline abstract_t">Kuo MT, Hu TH, Hung CH, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019; 49:218.</a></li><li><a class="nounderline abstract_t">Su TH, Yang HC, Tseng TC, et al. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. J Infect Dis 2018; 217:1193.</a></li><li><a class="nounderline abstract_t">Papatheodoridis GV, Sypsa V, Dalekos G, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol 2018; 68:1129.</a></li><li><a class="nounderline abstract_t">Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017; 66:1444.</a></li><li><a class="nounderline abstract_t">Dave S, Park S, Murad MH, et al. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Hepatology 2021; 73:68.</a></li><li><a class="nounderline abstract_t">Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5:1039.</a></li><li><a class="nounderline abstract_t">Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021; 27:402.</a></li><li><a class="nounderline abstract_t">Choi J, Kim HJ, Lee J, et al. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol 2019; 5:30.</a></li><li><a class="nounderline abstract_t">Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015; 62:363.</a></li><li><a class="nounderline abstract_t">Pol S, ANRS/AFEF study group. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther 2021; 53:616.</a></li><li><a class="nounderline abstract_t">Papatheodoridis GV, Dalekos GN, Idilman R, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2020; 73:1037.</a></li></ol></div><div id="topicVersionRevision">Topic 3653 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21364549" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16525137" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17983800" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20049753" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683932" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26510638" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19065670" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24905092" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26566246" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25190434" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25348661" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16525138" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19070393" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563196" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21762311" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22571899" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19280622" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24395227" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185191" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26566064" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : AASLD guidelines for treatment of chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22436845" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090296" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24583247" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28067752" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29089265" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24151397" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21503940" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21254162" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20006394" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23389810" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19937695" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044806" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22659518" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20646776" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328117" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22233350" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29228519" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32583915" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32329638" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306800" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170683" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26523639" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24188363" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744454" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29893893" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484881" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29300980" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29427727" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28622419" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32277491" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33007228" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34157830" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30267080" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25195548" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33464621" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553667" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
